MIRABEGRON AND UAS OUTCOMES DURING RIRS
THE EFFECT OF PREOPERATIVE MIRABEGRON ON URETERAL ACCESS SHEATH INSERTION SUCCESS AND URETERAL INJURY DURING RETROGRADE INTRARENAL SURGERY: A RETROSPECTIVE COMPARATIVE STUDY
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Altındağ
-
Ankara, Altındağ, Turkey (Türkiye)
- Ankara Training and Research Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- patients scheduled for RIRS due to kidney stones
Exclusion Criteria:
- preoperative ureteral stenting,
- ureteral strictures, history of ureteral or bladder surgery,
- anatomical abnormalities of the urinary tract,
- active urinary tract infection,
- pregnancy,
- uncontrolled hypertension (systolic blood pressure ≥180 mmHg, diastolic blood pressure ≥110 mmHg),
- use of medications affecting ureteral smooth muscle tone
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Mirabegron Group
Patients using mirabegron for overactive bladder and scheduled for retrograde intrarenal surgery due to kidney stones.
|
In our study, we evaluated the üreteral access sheath insertion rate in patients already using mirabegron for overactive bladder and scheduled for RIRS surgery for kidney stones.
No additional intervention was performed beyond the routine surgical procedure.
|
|
Control Group
Not using mirabegron and scheduled retrograde intrarenal surgery due to kidney stones.
|
In our study, we evaluated the üreteral access sheath insertion rate in patients already using mirabegron for overactive bladder and scheduled for RIRS surgery for kidney stones.
No additional intervention was performed beyond the routine surgical procedure.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Ureteral access sheath insertion rate
Time Frame: From January 2018 to October 2021
|
From January 2018 to October 2021
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Ureteral injury rate
Time Frame: From January 2018 to October 2024
|
From January 2018 to October 2024
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
General Publications
- Akinci A, Sanci A, Babayigit M, Gogus C. Does preoperative alpha-blocker use affect the results of flexible ureterorenoscopy? Actas Urol Esp (Engl Ed). 2025 Nov;49(9):501836. doi: 10.1016/j.acuroe.2025.501836. Epub 2025 Sep 10. English, Spanish.
- Ermis O, Sabuncu K, Kactan C, Karakus B, Surmeli B, Boz MY, Horuz R. Mirabegron administration for the prevention of ureteral injuries during ureteral access sheath insertion. World J Urol. 2026 Jan 27;44(1):130. doi: 10.1007/s00345-026-06225-3.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urogenital Diseases
- Male Urogenital Diseases
- Calculi
- Pathological Conditions, Anatomical
- Kidney Diseases
- Urologic Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urolithiasis
- Urinary Calculi
- Nephrolithiasis
- Pathological Conditions, Signs and Symptoms
- Kidney Calculi
Other Study ID Numbers
Other Study ID Numbers
- UASPULS2026
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.